The same effect had not been observed in the subcutaneously dosed group dmae porto alegre.

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS sufferers with positive results Apitope, the drug advancement and discovery company centered on treating the underlying cause of autoimmune diseases, announced completion with excellent results of its second Phase I scientific trial of ATX-MS-1467 today. Study of the MRI results demonstrated a substantial decrease in the number of contrast-enhancing human brain lesions in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467 dmae porto alegre .